Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.49 |
| ▸ | ESR1 | P03372 | 4/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913538 | 0.88 | ESR1 (0.49) | ABHD6ESR1ESR2ACKR3EP300 | |
| SCHEMBL13539115 | 0.84 | ABHD6 (0.41) | ABHD6ESR1ESR2ACKR3HTR5A | |
| SCHEMBL587897 | 0.82 | ABHD6 (0.69) | ABHD6ESR1ESR2EP300CREBBP | |
| SCHEMBL25604192 | 0.81 | ESR1 (0.56) | ABHD6ESR1ESR2EP300CREBBP | |
| SCHEMBL14678121 | 0.80 | ESR1 (0.44) | ABHD6ESR1ESR2ACKR3EP300 | |
| SCHEMBL3885156 | 0.80 | ESR1 (0.51) | ABHD6ESR1ESR2ACKR3EP300 | |
| SCHEMBL17130540 | 0.80 | ESR1 (0.55) | ABHD6ESR1ESR2EP300CREBBP | |
| SCHEMBL25589681 | 0.79 | ABHD6 (0.49) | ABHD6ESR1ESR2EP300CREBBP | |
| SCHEMBL31303813 | 0.79 | ESR2 (0.51) | ABHD6ESR2 | |
| SCHEMBL22530733 | 0.79 | ESR2 (0.51) | ABHD6ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198274-B2 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198274-B2 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | MAOB, MAOA, TPH1 | ABHD6 3186/4885ESR1 2065/4885ESR2 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.